雅培收購 Exact Sciences 以擴展癌症篩檢業務
Abbott Acquires Exact Sciences to Expand Cancer Screening Business
於2026年3月23日，醫療保健巨頭雅培實驗室（Abbott Laboratories）以210億美元完成了對Exact Sciences的收購。
On March 23, 2026, healthcare giant Abbott Laboratories finalized its acquisition of Exact Sciences for $21 billion.
這筆戰略性交易標誌著其在價值600億美元的癌症篩查和精準腫瘤診斷市場邁出了重要的一步。
This strategic deal marks a major expansion into the $60 billion cancer screening and precision oncology diagnostics market.
透過將Exact Sciences納入其產品組合，雅培旨在建立一個涵蓋從早期檢測到監測癌症復發（ㄈㄨˋㄈㄚ）的全面診斷生態系統。
By adding Exact Sciences to its portfolio, Abbott aims to build a comprehensive diagnostic ecosystem that covers everything from early detection to monitoring cancer recurrence.
此合併案包含的關鍵產品有：用於非侵入性大腸癌篩檢的Cologuard，以及用於個人化乳癌治療的基因檢測Oncotype DX。
Key products included in the merger are Cologuard, a non-invasive colorectal cancer test, and Oncotype DX, a genomic test for personalized breast cancer treatment.
此項收購反映了醫療科技產業中，企業尋求整合整個技術生態系統的平台整合趨勢。
This acquisition reflects a growing trend in the medical technology industry toward platform consolidation, where companies seek to integrate entire technological ecosystems.
對雅培而言，這筆交易也是關鍵的成長槓桿，有助於在後疫情時代新冠肺炎檢測需求下降後，實現收入來源的多元化（ㄉㄨㄛㄩㄢˊㄏㄨㄚˋ）。
For Abbott, the deal also serves as a critical growth lever, helping to diversify revenue streams following the post-pandemic decline in demand for COVID-19 testing.
